Chen Z, Sun Z, Zhang Z, Lei C, Ren Z, Di Y
Front Oncol. 2025; 15:1498927.
PMID: 40040724
PMC: 11876025.
DOI: 10.3389/fonc.2025.1498927.
Azeem M, Ur Rehman A, Rasheed S, Shahzad A, Javed M, Jamil Q
BMC Cancer. 2025; 25(1):331.
PMID: 39994602
PMC: 11849154.
DOI: 10.1186/s12885-025-13515-3.
Swaroop S, Biswas S, Mehta S, Aggarwal A, Arora U, Agarwal S
J Clin Med. 2025; 14(3).
PMID: 39941701
PMC: 11818670.
DOI: 10.3390/jcm14031034.
Mittal A, Kim M, Dunn S, Wright K, Gyawali B
EClinicalMedicine. 2025; 76():102824.
PMID: 39764569
PMC: 11701476.
DOI: 10.1016/j.eclinm.2024.102824.
Herr S, Kite T, Vyas P, Karlovits S, Yu A, Wegner R
J Neurooncol. 2024; 171(3):581-588.
PMID: 39543050
PMC: 11729084.
DOI: 10.1007/s11060-024-04873-2.
Outcomes that matter to patients with cancer: living longer and living better.
Tregear M, Visco F
EClinicalMedicine. 2024; 76:102833.
PMID: 39309725
PMC: 11415949.
DOI: 10.1016/j.eclinm.2024.102833.
Next-generation sequencing-based evaluation of the actionable landscape of genomic alterations in solid tumors: the "MOZART" prospective observational study.
Schettini F, Sirico M, Loddo M, Williams G, Hardisty K, Scorer P
Oncologist. 2024; 30(1).
PMID: 39177668
PMC: 11783315.
DOI: 10.1093/oncolo/oyae206.
Treatment Preferences Among Patients with Renal Cell Carcinoma: Results from a Discrete Choice Experiment.
Ornstein M, Rosenblatt L, Yin X, Del Tejo V, Guttenplan S, Ejzykowicz F
Patient Prefer Adherence. 2024; 18:1729-1739.
PMID: 39161803
PMC: 11332422.
DOI: 10.2147/PPA.S460994.
Density of tertiary lymphoid structures predicts clinical outcome in breast cancer brain metastasis.
Zhao Y, Fan Z, Tao B, Du Z, Shi Z
J Immunother Cancer. 2024; 12(7).
PMID: 39067874
PMC: 11284839.
DOI: 10.1136/jitc-2024-009232.
Survival prediction landscape: an in-depth systematic literature review on activities, methods, tools, diseases, and databases.
Abbasi A, Asim M, Ahmed S, Vollmer S, Dengel A
Front Artif Intell. 2024; 7:1428501.
PMID: 39021434
PMC: 11252047.
DOI: 10.3389/frai.2024.1428501.
Do proton pump inhibitors affect the effectiveness of cyclin-dependent kinase 4/6 inhibitors in advanced HR positive, HER2 negative breast cancer? A meta-analysis.
de Moraes F, Pereira C, Sano V, de Laia E, Stecca C, Burbano R
Front Pharmacol. 2024; 15:1352224.
PMID: 38769999
PMC: 11102992.
DOI: 10.3389/fphar.2024.1352224.
Improving the predictive accuracy of efficacy evaluation using tumor orthotopic transplant and resection model.
Li X, Luo L, Qian H
Front Pharmacol. 2024; 15:1309876.
PMID: 38476330
PMC: 10927943.
DOI: 10.3389/fphar.2024.1309876.
Targeted inhibition of the HNF1A/SHH axis by triptolide overcomes paclitaxel resistance in non-small cell lung cancer.
Li L, Yang L, Liu L, Liu F, Li A, Zhu Y
Acta Pharmacol Sin. 2024; 45(5):1060-1076.
PMID: 38228910
PMC: 11053095.
DOI: 10.1038/s41401-023-01219-y.
Long-term follow up of patients with WHO grade 2 oligodendroglioma.
Carstam L, Latini F, Solheim O, Bartek Jr J, Pedersen L, Zetterling M
J Neurooncol. 2023; 164(1):65-74.
PMID: 37603235
PMC: 10462563.
DOI: 10.1007/s11060-023-04368-6.
AhRR and PPP1R3C: Potential Prognostic Biomarkers for Serous Ovarian Cancer.
Ardizzoia A, Jemma A, Redaelli S, Silva M, Bentivegna A, Lavitrano M
Int J Mol Sci. 2023; 24(14).
PMID: 37511212
PMC: 10380391.
DOI: 10.3390/ijms241411455.
Making Sense of Composite Endpoints in Clinical Research.
Baracaldo-Santamaria D, Feliciano-Alfonso J, Ramirez-Grueso R, Rojas-Rodriguez L, Dominguez-Dominguez C, Calderon-Ospina C
J Clin Med. 2023; 12(13).
PMID: 37445406
PMC: 10342974.
DOI: 10.3390/jcm12134371.
Survival After Implementation of a Decision Support Tool to Facilitate Evidence-Based Cancer Treatment.
Ojha R, Lu Y, Narra K, Meadows R, Gehr A, Mantilla E
JCO Clin Cancer Inform. 2023; 7:e2300001.
PMID: 37343196
PMC: 10569767.
DOI: 10.1200/CCI.23.00001.
Model-based prediction of progression-free survival for combination therapies in oncology.
Baaz M, Cardilin T, Jirstrand M
CPT Pharmacometrics Syst Pharmacol. 2023; 12(9):1227-1237.
PMID: 37300376
PMC: 10508530.
DOI: 10.1002/psp4.13003.
Nutri-PEITC Jelly Significantly Improves Progression-Free Survival and Quality of Life in Patients with Advanced Oral and Oropharyngeal Cancer: A Blinded Randomized Placebo-Controlled Trial.
Lam-Ubol A, Sukhaboon J, Rasio W, Tupwongse P, Tangshewinsirikul T, Trachootham D
Int J Mol Sci. 2023; 24(9).
PMID: 37175527
PMC: 10177844.
DOI: 10.3390/ijms24097824.
Personalised therapeutic approaches to glioblastoma: A systematic review.
Mowforth O, Brannigan J, El Khoury M, Partha Sarathi C, Bestwick H, Bhatti F
Front Med (Lausanne). 2023; 10:1166104.
PMID: 37122327
PMC: 10140534.
DOI: 10.3389/fmed.2023.1166104.
